Day One Biopharmaceuticals to Acquire Mersana Therapeutics

Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately $285 million

Read more at globenewswire.com